Skip To Main Content
Melisande Addison on Muck Rack

Melisande Addison

As seen in: medRxiv
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Melisande

Contact Melisande, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Prediction of acetaminophen-induced hepatotoxicity in acetylcysteine-treated patients using routine admission biomarkers

|
By Christopher Humphries, Alastair M Kilpatrick, Melisande Addison
| medRxiv
J.W.D. holds a patent on a new single-biomarker liver toxicity point-of-care test. S.J.F. is co-founder of Resolution Therapeutics, which is developing a macrophage cell therapy product to treat patients at risk of liver decompensation. A.M.K. is a consultant to Resolution Therapeutics.
Open in Who Shared Issue with article?

Macrophage Therapy for Acute Liver Injury (MAIL): a Phase 1 Randomised, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Activity of Allogeneic Alternatively Activated Macrophages in Patients with Paracetamol-induced Acute Liver In…

|
By Christopher Humphries, Guruprasad P. Aithal, Julia A. Boyd, Melisande Addison
| medRxiv
All authors acknowledge that work for the MAIL Trial and publication of this manuscript is supported by MRC and CSO funding. GA: consulting fees from Clinipace, GSK, Amryth, Pfizer, DNDi, BenevolentAI Bio, PureTech LYT, Merck, Agios, Astra Zeneca, Suzhou MDCE. JCa: advisor to, founding member of, and stock options in Resolution Therapeutics, multiple patents related to delivery of macrophage cell therapy.
Open in Who Shared Issue with article?
See all 2 articles